NUAK2 amplification coupled with PTEN deficiency promotes melanoma development via CDK Activation

Takeshi Namiki, Tomonori Yaguchi, Kenta Nakamura, Julio C. Valencia, Sergio G. Coelho, Lanlan Yin, Masakazu Kawaguchi, Wilfred D. Vieira, Yasuhiko Kaneko, Atsushi Tanemura, Ichiro Katayama, Hiroo Yokozeki, Yutaka Kawakami, Vincent J. Hearing

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The AMPK-related kinase NUAK2 has been implicated in melanoma growth and survival outcomes, but its therapeutic utility has yet to be confirmed. In this study, we show how its genetic amplification in PTEN-deficient melanomas may rationalize the use of CDK2 inhibitors as a therapeutic strategy. Analysis of array-CGH data revealed that PTEN deficiency is coupled tightly with genomic amplification encompassing the NUAK2 locus, a finding strengthened by immunohistochemical evidence that phospho-Akt overexpression was correlated with NUAK2 expression in clinical specimens of acral melanoma. Functional studies in melanoma cells showed that inactivation of the PI3K pathway upregulatedp21 expression and reduced the number of cells in S phase. NUAK2 silencing and inactivation of the PI3K pathway efficiently controlled CDK2 expression, whereas CDK2 inactivation specifically abrogated the growth of NUAK2-amplified and PTEN-deficient melanoma cells. Immunohistochemical analyses confirmed an association of CDK2 expression with NUAK2 amplification and p-Akt expression in melanomas. Finally, pharmacologic inhibition of CDK2 was sufficient to suppress the growth of NUAK2-amplified and PTEN-deficient melanoma cells in vitro and in vivo. Overall, our results show how CDK2 blockade may offer a promising therapy for genetically defined melanomas, where NUAK2 is amplified and PTEN is deleted.

Original languageEnglish
Pages (from-to)2708-2715
Number of pages8
JournalCancer Research
Volume75
Issue number13
DOIs
Publication statusPublished - 2015 Jul 1

Fingerprint

Melanoma
Phosphatidylinositol 3-Kinases
Growth
S Phase
Therapeutics
Extremities
Cell Count

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Namiki, T., Yaguchi, T., Nakamura, K., Valencia, J. C., Coelho, S. G., Yin, L., ... Hearing, V. J. (2015). NUAK2 amplification coupled with PTEN deficiency promotes melanoma development via CDK Activation. Cancer Research, 75(13), 2708-2715. https://doi.org/10.1158/0008-5472.CAN-13-3209

NUAK2 amplification coupled with PTEN deficiency promotes melanoma development via CDK Activation. / Namiki, Takeshi; Yaguchi, Tomonori; Nakamura, Kenta; Valencia, Julio C.; Coelho, Sergio G.; Yin, Lanlan; Kawaguchi, Masakazu; Vieira, Wilfred D.; Kaneko, Yasuhiko; Tanemura, Atsushi; Katayama, Ichiro; Yokozeki, Hiroo; Kawakami, Yutaka; Hearing, Vincent J.

In: Cancer Research, Vol. 75, No. 13, 01.07.2015, p. 2708-2715.

Research output: Contribution to journalArticle

Namiki, T, Yaguchi, T, Nakamura, K, Valencia, JC, Coelho, SG, Yin, L, Kawaguchi, M, Vieira, WD, Kaneko, Y, Tanemura, A, Katayama, I, Yokozeki, H, Kawakami, Y & Hearing, VJ 2015, 'NUAK2 amplification coupled with PTEN deficiency promotes melanoma development via CDK Activation', Cancer Research, vol. 75, no. 13, pp. 2708-2715. https://doi.org/10.1158/0008-5472.CAN-13-3209
Namiki, Takeshi ; Yaguchi, Tomonori ; Nakamura, Kenta ; Valencia, Julio C. ; Coelho, Sergio G. ; Yin, Lanlan ; Kawaguchi, Masakazu ; Vieira, Wilfred D. ; Kaneko, Yasuhiko ; Tanemura, Atsushi ; Katayama, Ichiro ; Yokozeki, Hiroo ; Kawakami, Yutaka ; Hearing, Vincent J. / NUAK2 amplification coupled with PTEN deficiency promotes melanoma development via CDK Activation. In: Cancer Research. 2015 ; Vol. 75, No. 13. pp. 2708-2715.
@article{697cf294dcc1412a889c7c04a1224ed5,
title = "NUAK2 amplification coupled with PTEN deficiency promotes melanoma development via CDK Activation",
abstract = "The AMPK-related kinase NUAK2 has been implicated in melanoma growth and survival outcomes, but its therapeutic utility has yet to be confirmed. In this study, we show how its genetic amplification in PTEN-deficient melanomas may rationalize the use of CDK2 inhibitors as a therapeutic strategy. Analysis of array-CGH data revealed that PTEN deficiency is coupled tightly with genomic amplification encompassing the NUAK2 locus, a finding strengthened by immunohistochemical evidence that phospho-Akt overexpression was correlated with NUAK2 expression in clinical specimens of acral melanoma. Functional studies in melanoma cells showed that inactivation of the PI3K pathway upregulatedp21 expression and reduced the number of cells in S phase. NUAK2 silencing and inactivation of the PI3K pathway efficiently controlled CDK2 expression, whereas CDK2 inactivation specifically abrogated the growth of NUAK2-amplified and PTEN-deficient melanoma cells. Immunohistochemical analyses confirmed an association of CDK2 expression with NUAK2 amplification and p-Akt expression in melanomas. Finally, pharmacologic inhibition of CDK2 was sufficient to suppress the growth of NUAK2-amplified and PTEN-deficient melanoma cells in vitro and in vivo. Overall, our results show how CDK2 blockade may offer a promising therapy for genetically defined melanomas, where NUAK2 is amplified and PTEN is deleted.",
author = "Takeshi Namiki and Tomonori Yaguchi and Kenta Nakamura and Valencia, {Julio C.} and Coelho, {Sergio G.} and Lanlan Yin and Masakazu Kawaguchi and Vieira, {Wilfred D.} and Yasuhiko Kaneko and Atsushi Tanemura and Ichiro Katayama and Hiroo Yokozeki and Yutaka Kawakami and Hearing, {Vincent J.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1158/0008-5472.CAN-13-3209",
language = "English",
volume = "75",
pages = "2708--2715",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - NUAK2 amplification coupled with PTEN deficiency promotes melanoma development via CDK Activation

AU - Namiki, Takeshi

AU - Yaguchi, Tomonori

AU - Nakamura, Kenta

AU - Valencia, Julio C.

AU - Coelho, Sergio G.

AU - Yin, Lanlan

AU - Kawaguchi, Masakazu

AU - Vieira, Wilfred D.

AU - Kaneko, Yasuhiko

AU - Tanemura, Atsushi

AU - Katayama, Ichiro

AU - Yokozeki, Hiroo

AU - Kawakami, Yutaka

AU - Hearing, Vincent J.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - The AMPK-related kinase NUAK2 has been implicated in melanoma growth and survival outcomes, but its therapeutic utility has yet to be confirmed. In this study, we show how its genetic amplification in PTEN-deficient melanomas may rationalize the use of CDK2 inhibitors as a therapeutic strategy. Analysis of array-CGH data revealed that PTEN deficiency is coupled tightly with genomic amplification encompassing the NUAK2 locus, a finding strengthened by immunohistochemical evidence that phospho-Akt overexpression was correlated with NUAK2 expression in clinical specimens of acral melanoma. Functional studies in melanoma cells showed that inactivation of the PI3K pathway upregulatedp21 expression and reduced the number of cells in S phase. NUAK2 silencing and inactivation of the PI3K pathway efficiently controlled CDK2 expression, whereas CDK2 inactivation specifically abrogated the growth of NUAK2-amplified and PTEN-deficient melanoma cells. Immunohistochemical analyses confirmed an association of CDK2 expression with NUAK2 amplification and p-Akt expression in melanomas. Finally, pharmacologic inhibition of CDK2 was sufficient to suppress the growth of NUAK2-amplified and PTEN-deficient melanoma cells in vitro and in vivo. Overall, our results show how CDK2 blockade may offer a promising therapy for genetically defined melanomas, where NUAK2 is amplified and PTEN is deleted.

AB - The AMPK-related kinase NUAK2 has been implicated in melanoma growth and survival outcomes, but its therapeutic utility has yet to be confirmed. In this study, we show how its genetic amplification in PTEN-deficient melanomas may rationalize the use of CDK2 inhibitors as a therapeutic strategy. Analysis of array-CGH data revealed that PTEN deficiency is coupled tightly with genomic amplification encompassing the NUAK2 locus, a finding strengthened by immunohistochemical evidence that phospho-Akt overexpression was correlated with NUAK2 expression in clinical specimens of acral melanoma. Functional studies in melanoma cells showed that inactivation of the PI3K pathway upregulatedp21 expression and reduced the number of cells in S phase. NUAK2 silencing and inactivation of the PI3K pathway efficiently controlled CDK2 expression, whereas CDK2 inactivation specifically abrogated the growth of NUAK2-amplified and PTEN-deficient melanoma cells. Immunohistochemical analyses confirmed an association of CDK2 expression with NUAK2 amplification and p-Akt expression in melanomas. Finally, pharmacologic inhibition of CDK2 was sufficient to suppress the growth of NUAK2-amplified and PTEN-deficient melanoma cells in vitro and in vivo. Overall, our results show how CDK2 blockade may offer a promising therapy for genetically defined melanomas, where NUAK2 is amplified and PTEN is deleted.

UR - http://www.scopus.com/inward/record.url?scp=84942916550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942916550&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-3209

DO - 10.1158/0008-5472.CAN-13-3209

M3 - Article

C2 - 25832654

AN - SCOPUS:84942916550

VL - 75

SP - 2708

EP - 2715

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 13

ER -